Martin Gengenbacher, Ph.D. of the Hackensack Meridian CDI (IMAGE)
Caption
A new study led by scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) reveals that combining an immunotherapy with the traditional Bacille Calmette-Guérin (BCG) vaccine drastically lowers the risk of TB relapse in preclinical models.
Credit
Hackensack Meridian Health
Usage Restrictions
Usage with permission
License
Original content